ATR and lung cancer: Regarding the subtypes of lung cancer (Figure 2C), the top five mutational rates are as follows: RAD51C/FANCO at 25% in lung adenosquamous carcinoma, ATR at 22.7% in combined small cell lung carcinoma, 17% in adenocarcinoma, and 16.5% in squamous cell carcinoma, BRIP1/FANCJ at 18.5% in adenocarcinoma, ATM at 18% in large cell lung carcinoma, and BRCA1/FANCS at 16.5% in large cell neuroendocrine carcinoma.